» Articles » PMID: 11232021

Luteinzing Hormone Activity in Menotropins Optimizes Folliculogenesis and Treatment in Controlled Ovarian Stimulation

Overview
Specialty Endocrinology
Date 2001 Mar 7
PMID 11232021
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

Although the role that LH plays in folliculogenesis is still controversial, recent evidence points toward facilitatory actions of LH activity in ovulation induction. Thus, we compared the response to either highly purified FSH (75 IU FSH/ampoule; group A, 25 subjects) or human menopausal gonadotropin (75 IU FSH and 75 IU LH/ampoule; group B, 25 subjects) in normoovulatory GnRH agonist-suppressed women, candidates for intrauterine insemination. A fixed regimen of 2 daily ampoules of highly purified FSH or human menopausal gonadotropin was administered in the initial 14 days of treatment; menotropin dose adjustments were allowed thereafter. Treatment was monitored with daily blood samples for the measurement of LH, FSH, 17beta-estradiol (E(2)), progesterone, testosterone, hCG, inhibin A, and inhibin B, and transvaginal pelvic ultrasound was performed at 2-day intervals. Although preovulatory E(2) levels were similar, both the duration of treatment (16.1 +/- 0.8 vs. 12.6 +/- 0.5 days; P< 0.005) and the per cycle menotropin dose (33.6 +/- 2.4 vs. 23.6 +/- 1.1 ampoules; P < 0.005) were lower in group B. In the initial 14 treatment days the area under the curve of FSH, progesterone, testosterone, inhibin A, and inhibin B did not differ between the 2 groups, whereas LH, hCG, and E(2) areas under the curve were higher in group B. The occurrence of small follicles (<10 mm) and the inhibin B/A ratio in the late follicular phase were significantly reduced in group B. A nonsignificant trend toward a higher multiple gestation rate was present in group A (60% vs. 17%). We conclude that ovulation induction with LH activity-containing menotropins is associated with 1) shorter treatment duration, 2) lower menotropin consumption, and 3) reduced development of small ovarian follicles. These features can be exploited to develop regimens that optimize treatment outcome, lower costs, and reduce occurrence of complications such as multiple gestation and ovarian hyperstimulation.

Citing Articles

FSH/LH co-stimulation in Advanced Maternal Age (AMA) and hypo-responder patients - Arabian gulf delphi consensus group.

Awwad J, Peramo B, Elgeyoushi B, Melado L, Salame A, Chawla M Front Endocrinol (Lausanne). 2024; 15:1506332.

PMID: 39726844 PMC: 11669953. DOI: 10.3389/fendo.2024.1506332.


Recombinant human luteinizing hormone increases endometrial thickness in women undergoing assisted fertility treatments: a systematic review and meta-analysis.

Mao R, Hou X, Feng X, Wang R, Fei X, Zhao J Front Pharmacol. 2024; 15:1434625.

PMID: 39135787 PMC: 11317380. DOI: 10.3389/fphar.2024.1434625.


A Narrative Review Discussing the Efficiency of Personalized Dosing Algorithm of Follitropin Delta for Ovarian Stimulation and the Reproductive and Clinical Outcomes.

Doroftei B, Ilie O, Anton N, Marcu O, Scripcariu I, Ilea C Diagnostics (Basel). 2023; 13(2).

PMID: 36672987 PMC: 9858569. DOI: 10.3390/diagnostics13020177.


A randomized, controlled, first-in-patient trial of choriogonadotropin beta added to follitropin delta in women undergoing ovarian stimulation in a long GnRH agonist protocol.

Sanchez M, Visnova H, Larsson P, Andersen C, Filicori M, Blockeel C Hum Reprod. 2022; 37(6):1161-1174.

PMID: 35451013 PMC: 9156848. DOI: 10.1093/humrep/deac061.


Effect of rLH Supplementation during Controlled Ovarian Stimulation for IVF: Evidence from a Retrospective Analysis of 1470 Poor/Suboptimal/Normal Responders Receiving Either rFSH plus rLH or rFSH Alone.

Canosa S, Carosso A, Mercaldo N, Ruffa A, Evangelista F, Bongioanni F J Clin Med. 2022; 11(6).

PMID: 35329901 PMC: 8954443. DOI: 10.3390/jcm11061575.